Infinity Pharmaceuticals, Inc., is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies.

Biotechnology

Pharmaceutical

Infinity Pharmaceuticals

Infinity Pharmaceuticals' headquarters in Cambridge, MA, United States

Eva Huang

Idelfonso Méndez

Devon Jones

Heywood Ellenburg

Mohammed Nurullah

Saveria Cristiano

Steve Cucinotta

Somarajan Nair

Naglaa Fikry

Liya Megerssa

Jasim Uddin

Khaled Oukasha

Joseph McPherson

Deirdre Casale

Diana Auclair

Paula Flynn

Sabrina Zhao

Beda Bischof

Ergun Kirlikovali

Nermeen Hamdy

Sarah Khalaf

Andres A Pena Paz

Rich Demarco

Randall Kester

David Beier

Anthony Evnin

Michael Postow

Roy Herbst

Dmitry Gabrilovich

Stephen Hodi

Richard Gaynor

David H. Munn

Toni Choueiri

Jeffery Kutok

Norman C. Selby

Padmanee Sharma

Description